Neurokine Pharmaceuticals Inc. is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. Its research and development activities are focused on assessing known drugs and compounds, developing hypotheses concerning their usage for new indications (diseases), and conducting experimentation and clinical research to test those hypotheses. As of January 31, 2014, the Company had identified two anti-inflammatory products, which included NK-001 and NK-002. NK-001 holds prospect for the treatment of neurocognitive impairment. NK-002 holds prospect for treatment of Alzheimer�s disease. Both of the Company�s planned products are in the development stage.